Last updated: September 8, 2026
Encorafenib, marketed as Braftovi by Pfizer, is a commercially established BRAF-targeted oncology drug with three FDA-approved uses: BRAF V600E-mutant unresectable or metastatic melanoma with binimetinib, BRAF V600E-mutant metastatic colorectal cancer with cetuximab, and BRAF V600E-mutant metastatic non-small-cell lung cancer with binimetinib. Its financial trajectory has improved through indication expansion, broader testing for BRAF mutations, and Pfizer’s global commercialization infrastructure. The principal risks are combination dependence, competition from other BRAF/MEK regimens, limited biomarker prevalence, and generic entry after the core composition patents expire.
What is encorafenib and which products contain it?
Encorafenib is an oral, small-molecule BRAF inhibitor that selectively inhibits mutant BRAF kinase signaling. The product is sold as Braftovi capsules and is generally administered in combination with another targeted agent.
| Product |
Active ingredient |
Primary combination |
FDA status |
| Braftovi |
Encorafenib |
Binimetinib |
Approved for BRAF V600E or V600K-mutant unresectable or metastatic melanoma |
| Braftovi |
Encorafenib |
Cetuximab |
Approved for BRAF V600E-mutant metastatic colorectal cancer after prior therapy |
| Braftovi |
Encorafenib |
Binimetinib |
Approved for BRAF V600E-mutant metastatic NSCLC |
The FDA approved Braftovi plus binimetinib for melanoma in June 2018. Braftovi plus cetuximab received approval for BRAF V600E-mutant metastatic colorectal cancer in April 2018. The FDA expanded Braftovi plus binimetinib into BRAF V600E-mutant metastatic NSCLC in October 2023 based on the PHAROS trial (FDA, 2018a, 2018b, 2023).
How large is the addressable market for encorafenib?
The addressable market is biomarker-defined rather than population-wide. BRAF V600 mutations occur in approximately 40% to 50% of metastatic melanoma cases, about 8% to 12% of colorectal cancers, and approximately 1% to 2% of NSCLC cases. The number of eligible patients is therefore modest, but treatment value is high because BRAF-mutant disease often has poor outcomes without targeted therapy.
Melanoma market
Melanoma was the original commercial market for Braftovi. The Braftovi-binimetinib regimen competes with:
- Tafinlar, or dabrafenib, plus Mekinist, or trametinib, from Novartis.
- Zelboraf, or vemurafenib, plus Cotellic, or cobimetinib, from Roche.
- Immunotherapy regimens, including anti-PD-1 and anti-CTLA-4 combinations.
Braftovi-binimetinib has differentiated on dosing flexibility, clinical activity, and the depth of its clinical data. The melanoma market is mature, however, and treatment selection depends on disease burden, symptom severity, central nervous system involvement, toxicity preferences, and prior immunotherapy.
Colorectal cancer market
The colorectal cancer indication has been commercially important because encorafenib is part of the principal FDA-approved targeted regimen for BRAF V600E-mutant metastatic colorectal cancer. Braftovi is used with cetuximab after prior systemic therapy.
The regimen benefits from a clear biomarker-treatment connection. BRAF V600E-mutant colorectal cancer is associated with aggressive disease and historically poor outcomes. Competitive pressure comes primarily from chemotherapy backbones, anti-EGFR antibodies, immunotherapy in selected patients, and emerging KRAS, HER2, and other molecularly targeted treatments rather than from another directly equivalent BRAF regimen.
NSCLC market
The NSCLC approval expanded the commercial opportunity but entered a crowded molecular oncology market. Braftovi-binimetinib competes with Tafinlar-Mekinist, which also targets BRAF V600E-mutant NSCLC, as well as treatment options for other driver mutations such as EGFR, ALK, ROS1, KRAS G12C, MET, RET, and HER2.
The NSCLC opportunity is smaller than the melanoma market by patient count. Its strategic value is the ability to reuse an existing regimen, manufacturing platform, safety database, and commercial organization in another biomarker-defined cancer.
What are Braftovi’s sales and financial trajectory?
Pfizer reports Braftovi sales as a product line but does not separately disclose revenue by indication, geography, combination partner, or patient population. Public annual-report data show sustained growth following the Array BioPharma acquisition.
| Fiscal year |
Approximate Braftovi revenue |
Strategic context |
| 2021 |
About $300 million |
Expansion of Pfizer commercial reach and continued melanoma uptake |
| 2022 |
About $480 million |
Growth in melanoma and colorectal cancer |
| 2023 |
About $640 million |
Continued demand and initial contribution from NSCLC approval |
Sources report slightly different presentations depending on whether figures are shown as reported revenue, constant-exchange-rate revenue, or product sales by geographic reporting category. Pfizer’s annual reports should control for investment and valuation work (Pfizer, 2022, 2023).
Why did revenue grow after commercialization?
Revenue growth has been driven by four factors:
- The Braftovi-binimetinib regimen established a durable melanoma franchise.
- The colorectal cancer indication created a second commercial use with a distinct patient population.
- Companion diagnostic testing increased identification of BRAF V600E-mutant disease.
- Pfizer expanded global sales, market access, and oncology distribution after acquiring Array.
Braftovi is sold as part of combination regimens, but Pfizer does not disclose the portion of sales attributable to melanoma, colorectal cancer, or NSCLC. The commercial value of the product is therefore linked to the full treatment ecosystem, including binimetinib and cetuximab utilization.
What is Pfizer’s revenue exposure to Braftovi?
Braftovi remains a small component of Pfizer’s overall revenue. Pfizer generated more than $50 billion in total revenue in 2023, while Braftovi contributed roughly $0.6 billion. The product is strategically relevant within Pfizer’s oncology portfolio but is not large enough to determine group-level financial performance.
The more material exposure is at the acquired Array oncology portfolio level. Pfizer paid approximately $11.4 billion, including assumed debt, to acquire Array in 2019. The acquisition also brought Mektovi, encorafenib’s melanoma combination partner, and other targeted oncology assets (Pfizer, 2019).
How does encorafenib compare with competing BRAF inhibitors?
| Attribute |
Encorafenib |
Dabrafenib |
Vemurafenib |
| Brand |
Braftovi |
Tafinlar |
Zelboraf |
| Principal MEK combination |
Binimetinib |
Trametinib |
Cobimetinib |
| Melanoma approval |
Yes |
Yes |
Yes |
| BRAF-mutant CRC approval |
Yes, with cetuximab |
No equivalent FDA-approved BRAF/EGFR regimen |
No |
| BRAF-mutant NSCLC approval |
Yes, with binimetinib |
Yes, with trametinib |
No |
| Manufacturer |
Pfizer |
Novartis |
Roche |
| Core market advantage |
CRC positioning and established melanoma regimen |
Broad BRAF/MEK presence |
Earlier market entry |
Encorafenib’s strongest competitive position is metastatic colorectal cancer. In melanoma and NSCLC, its commercial position depends more heavily on comparative tolerability, physician familiarity, payer access, dosing, and clinical sequencing.
What patents protect encorafenib and Braftovi?
Braftovi is protected by composition-of-matter, formulation, pharmaceutical-composition, and method-of-use patent rights. The most valuable rights are the patents covering encorafenib itself and its use in combination regimens.
Public patent records associate encorafenib with Array BioPharma and related entities later acquired by Pfizer. The principal U.S. composition patent family has an expiration period around 2030, subject to patent-term adjustment and any applicable patent-term extension. Later-issued formulation, salt, dosing, and combination patents may extend practical protection into the 2030s, but their scope and enforceability are narrower than the core compound patent.
| Protection category |
Commercial relevance |
Expected timing |
| Encorafenib composition patents |
Highest barrier to substitution |
Core expiry generally around 2030 |
| Pharmaceutical-composition patents |
May cover capsule or dosage-form characteristics |
Potentially later than core compound rights |
| Encorafenib-binimetinib use patents |
Supports melanoma and NSCLC indications |
May extend into the 2030s |
| Encorafenib-cetuximab use patents |
Supports BRAF-mutant colorectal cancer treatment |
Later-expiring method claims may apply |
| Manufacturing and process patents |
Can increase development cost for challengers |
Usually less decisive than composition claims |
The precise Orange Book position must be assessed against the current FDA listing because patents can be added, delisted, disclaimed, or challenged over time. The Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved small-molecule products (FDA, 2024a).
When does encorafenib lose exclusivity?
The principal commercial patent cliff is unlikely to occur before the end of the 2020s. The core composition protection is generally associated with an expiration around 2030, while later patents may affect the timing and scope of generic entry.
FDA regulatory exclusivity is separate from patent protection. Encorafenib received new chemical entity exclusivity with its first approval, but that five-year period has expired. Subsequent approvals may receive three-year exclusivity only when supported by qualifying new clinical investigations. Such exclusivity would protect the approved clinical change, not necessarily block all generic versions of the active ingredient.
A generic applicant could seek approval before patent expiry through an ANDA containing a Paragraph IV certification. Commercial entry would depend on litigation, settlement terms, court decisions, and the generic applicant’s ability to obtain approval without infringing enforceable claims.
What is the Paragraph IV and generic-entry risk for Braftovi?
The generic risk profile is moderate in the near term and higher after core composition protection expires.
Near-term risk
Near-term risk is constrained by:
- The technical complexity of reproducing a targeted oncology capsule.
- The need to address multiple listed patents.
- Possible litigation triggered by a Paragraph IV certification.
- The commercial need to obtain sufficient volume in a biomarker-defined market.
- Combination dependence, which can complicate substitution and payer adoption.
Post-core-patent risk
After core composition protection expires, a generic encorafenib product could compete on the active ingredient while Pfizer retains practical advantages in:
- Brand familiarity.
- Clinical guidelines and physician use.
- Combination positioning.
- Patient-support infrastructure.
- Manufacturing scale.
- Potential later-expiring formulation or method-of-use patents.
Generic entry may initially be limited to a label that avoids patented indications. This could create a skinny-label scenario in which the generic is approved for non-protected uses while Pfizer continues to market patented combinations.
No biosimilar risk applies because encorafenib is a synthetic small molecule, not a biologic. The relevant pathway is an ANDA, not a biosimilar application under the Public Health Service Act.
What litigation and settlement issues affect encorafenib?
Braftovi litigation risk centers on ANDA patent challenges, Orange Book listing disputes, claim construction, and the enforceability of formulation or method-of-use patents. A Paragraph IV notice would typically lead to patent litigation under the Hatch-Waxman framework and could trigger a 30-month stay of FDA approval for the challenged ANDA, subject to statutory exceptions.
The critical settlement variables would include:
- Earliest permitted generic launch date.
- Whether the settlement allows an authorized generic.
- Which indications are carved out.
- Whether Pfizer receives commercial payments or supply rights.
- Whether later-expiring patents remain enforceable.
- Whether multiple generic applicants receive different launch dates.
A settlement could preserve substantial Braftovi revenue even if an ANDA is approved before all listed patents expire. Conversely, a successful invalidity or noninfringement decision could accelerate entry and compress sales rapidly.
What manufacturing and intellectual-property barriers protect Braftovi?
Encorafenib is a small molecule, so it does not have the manufacturing complexity associated with monoclonal antibodies or cell therapies. The principal barriers are chemical-process control, impurity specifications, capsule formulation, bioequivalence, supply reliability, and regulatory documentation.
The most defensible intellectual-property assets are likely the original compound and selected clinical-use claims. Manufacturing patents can provide incremental protection, but they generally do not prevent a competent generic manufacturer from developing a noninfringing process.
Braftovi’s combination products create commercial, rather than purely manufacturing, barriers. A generic encorafenib supplier does not automatically control access to binimetinib, cetuximab, prescribing protocols, or payer pathways.
Which companies are challenging Pfizer in the encorafenib market?
The principal branded competitors are:
- Novartis, with dabrafenib and trametinib.
- Roche, with vemurafenib and cobimetinib.
- Bristol Myers Squibb and Merck, through immuno-oncology regimens used in melanoma and colorectal cancer.
- Generic manufacturers, once ANDA approvals and patent outcomes permit entry.
Competitive intensity will increase as more tumor types receive molecularly matched therapies. Pfizer’s ability to retain share depends on evidence in first-line and later-line settings, central nervous system activity, tolerability, combination durability, and continued biomarker testing.
What are the likely Braftovi launch scenarios?
| Scenario |
Timing |
Financial effect |
| No early generic challenge |
Before core expiry |
Continued growth or stable revenue |
| First generic after litigation |
Around core patent expiry |
Moderate price erosion followed by share loss |
| Multiple generics at launch |
After patent settlement or invalidity ruling |
Rapid price and volume erosion |
| Skinny-label generic |
Before all method patents expire |
Partial erosion, with Pfizer retaining protected indications |
| Successful later-patent defense |
Into the 2030s |
Longer brand tail, but litigation costs increase |
The most likely base case is a gradual transition rather than an immediate collapse. Braftovi’s patient population is relatively small, its use is specialist-driven, and combination treatment limits direct substitution. Generic oncology launches can still produce substantial price erosion because payers and specialty pharmacies have strong incentives to switch.
How strong is the encorafenib patent estate?
The estate is commercially meaningful but not uniformly strong across all claim types.
| Patent category |
Relative strength |
Reason |
| Core composition |
High until expiry |
Directly covers the active ingredient |
| Capsule formulation |
Medium |
May be designed around or challenged |
| Combination use |
Medium |
Depends on claim scope and approved indication |
| Method of treatment |
Variable |
Requires proof of claim applicability and infringement |
| Manufacturing process |
Low to medium |
Alternative processes may be available |
The acquisition by Pfizer improves enforcement capacity, global prosecution, and commercial coordination. It does not change the underlying expiry of the original patent families. Value increasingly shifts from the molecule itself to label breadth, clinical differentiation, and the timing of generic challenges.
What is the FDA and Orange Book status of Braftovi?
Braftovi is FDA-approved and listed in the Orange Book as a prescription small-molecule drug. Its regulatory status is supported by approved combination regimens rather than monotherapy. The current label includes melanoma, colorectal cancer, and NSCLC uses involving BRAF V600E or related BRAF mutation requirements depending on the indication (FDA, 2024b).
The label’s biomarker restrictions limit off-label expansion but improve treatment positioning where molecular testing identifies eligible patients. Continued commercial growth depends on testing rates, guideline placement, payer coverage, and evidence supporting earlier treatment lines.
Key Takeaways
- Encorafenib is Pfizer’s Braftovi, a BRAF inhibitor used in melanoma, colorectal cancer, and NSCLC.
- The colorectal cancer indication is its clearest differentiation because Braftovi plus cetuximab occupies a specialized BRAF V600E treatment position.
- Braftovi revenue increased from roughly $300 million in 2021 to approximately $640 million in 2023.
- Pfizer’s 2019 acquisition of Array BioPharma provided global ownership and commercial infrastructure.
- The core composition patent estate generally points to protection around 2030, with later formulation and method-of-use rights potentially extending into the 2030s.
- Generic risk is limited before core patent expiry but could accelerate through Paragraph IV litigation, settlements, or patent invalidation.
- Biosimilar competition does not apply because encorafenib is a synthetic small molecule.
- Long-term value depends on biomarker testing, combination efficacy, new indications, and Pfizer’s ability to defend later-expiring patents.
FAQs About Encorafenib Market and Exclusivity
What is the brand name for encorafenib?
Encorafenib is marketed as Braftovi. It is usually prescribed with binimetinib or cetuximab, depending on the cancer indication.
Is encorafenib approved as a standalone treatment?
Braftovi’s principal FDA-approved uses are combination regimens. It is paired with binimetinib for melanoma and NSCLC and with cetuximab for BRAF V600E-mutant colorectal cancer.
Does encorafenib have biosimilar competition?
No. Encorafenib is a synthetic small molecule and would face conventional generic competition through the ANDA pathway, not biosimilar competition.
Which cancer indication provides the strongest competitive position for Braftovi?
Metastatic colorectal cancer provides the clearest differentiation because Braftovi plus cetuximab is a targeted regimen specifically used for BRAF V600E-mutant disease.
What is the main investment risk for Pfizer’s Braftovi franchise?
The primary risk is loss of exclusivity after core patent protection expires, followed by rapid price erosion from generic encorafenib products. Clinical competition and the small biomarker-defined patient population are secondary risks.
References
-
Food and Drug Administration. (2018a). FDA approves encorafenib with binimetinib and cetuximab for metastatic colorectal cancer. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2018b). FDA approves encorafenib and binimetinib for metastatic melanoma. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with BRAF V600E mutation. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024b). Braftovi prescribing information. U.S. Department of Health and Human Services.
-
Pfizer Inc. (2019). Pfizer to acquire Array BioPharma. Pfizer investor relations.
-
Pfizer Inc. (2022). 2022 annual report. Pfizer Inc.
-
Pfizer Inc. (2023). 2023 annual report. Pfizer Inc.
